Full history for every metric is available with a Kvantra account
NeuroMetrix, Inc. (NURO)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 9 | 7 | 8 | 8 | 6 | 3 | 3 |
| Operating profit | $m | -9 | -9 | |||||
| Net profit | $m | -4 | -2 | -2 | -4 | -7 | -8 | -8 |
| EPS reported | $ | -3.96 | -4.03 | |||||
| Operating cashflow per share | $ | -3.62 | -3.62 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -3.62 | -3.62 | |||||
| Free cash flow | $m | -7 | -7 | |||||
| Net debt | $m | -13 | -13 | |||||
| Book value equity | $m | 14 | 14 | |||||
| Book value per share | $ | 7.27 | 6.98 | |||||
| Number of shares | m | 1.97 | 2.05 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.55 | 0.66 | |||||
| P/S LTM | x | 2.58 | 3.11 | |||||
| P/FCF LTM | x | -1.10 | -1.32 | |||||
| EV/EBITDA LTM | x | -0.76 | 0.44 | |||||
| EV/Sales LTM | x | 2.14 | -1.21 | |||||
| Earnings Yield LTM | % | -99.82% | -86.52% | |||||
| FCF Yield | % | -91.15% | -75.57% | |||||
| Quality | ||||||||
| ROE | % | -54.54% | -45.38% | |||||
| ROIC | % | -60.91% | -60.91% | |||||
| Operating margin | % | -289.57% | -289.57% | |||||
| Gross margin | % | 55.38% | 55.38% | |||||
| FCF/Sales | % | -235.04% | -235.04% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -48.61% | -48.61% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -66.40 | -66.40 | |||||
| Net Debt/EBITDA | x | 0.15 | 0.15 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -167.45% | -138.82% | |||||
| Net debt/Equity | x | -0.91 | -0.91 | |||||
| Gross debt/equity | x | 0.01 | 0.01 | |||||
Company overview
NeuroMetrix, Inc. is a healthcare company focused on creating, manufacturing, and distributing medical devices that stimulate and evaluate nerve function for both diagnostic and therapeutic applications. These products are available across a wide geographical area, including the United States, Europe, Japan, China, the Middle East, and Mexico. The company's core offerings include DPNCheck, a nerve conduction test used to identify and assess peripheral neuropathies such as diabetic peripheral neuropathy; Quell, a wearable device engineered for the relief and management of persistent pain; and the ADVANCE system, a dedicated platform for performing comprehensive nerve conduction studies. NeuroMetrix supplies its advanced solutions to a diverse clientele, encompassing managed care organizations, primary care providers, specialists like endocrinologists, podiatrists, various surgeons (including orthopedic and hand surgeons), occupational health practitioners, and neurology, pain medicine, and physical medicine and rehabilitation experts. Incorporated in 1996, the company's headquarters are located in Woburn, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
NeuroMetrix, Inc. (NURO)
NeuroMetrix, Inc. is a healthcare company focused on creating, manufacturing, and distributing medical devices that stimulate and evaluate nerve function for both diagnostic and therapeutic applications. These products are available across a wide geographical area, including the United States, Europe, Japan, China, the Middle East, and Mexico. The company's core offerings include DPNCheck, a nerve conduction test used to identify and assess peripheral neuropathies such as diabetic peripheral neuropathy; Quell, a wearable device engineered for the relief and management of persistent pain; and the ADVANCE system, a dedicated platform for performing comprehensive nerve conduction studies. NeuroMetrix supplies its advanced solutions to a diverse clientele, encompassing managed care organizations, primary care providers, specialists like endocrinologists, podiatrists, various surgeons (including orthopedic and hand surgeons), occupational health practitioners, and neurology, pain medicine, and physical medicine and rehabilitation experts. Incorporated in 1996, the company's headquarters are located in Woburn, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free